We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

112 hedge funds and large institutions have $263M invested in BioSpecifics Technologies Corp. in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $247M → $263M (+$16.1M)

8% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 36

0% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 16

2% less funds holding

Funds holding: 114112 (-2)

Holders
112
Holders Change
-2
Holders Change %
-1.75%
% of All Funds
2.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
39
Reduced
36
Closed
16
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BCA
126
Berman Capital Advisors
Georgia
-$1K -19 Closed
Federated Hermes
127
Federated Hermes
Pennsylvania
-$1K -7 Closed

BSTC Hedge Fund Activity: Q4 2019 in Review

112 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q4 2019, worth a combined $263M — up 6.5% from $247M a quarter earlier.

Fund positioning in BSTC was balanced in Q4 2019: 16 funds opened new positions, 16 closed out, 39 added to existing stakes and 36 trimmed.

The largest buyer was Russell Investments Group, adding an estimated $5.64M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $6.1M sold.

  • 112 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q4 2019, down from 114 in Q3 2019.
  • Funds reported $263M of BioSpecifics Technologies Corp. stock for Q4 2019, up 6.5% quarter-over-quarter.
  • 16 funds opened new BioSpecifics Technologies Corp. positions in Q4 2019 and 16 closed out, a net change of 0 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q4 2019 was Russell Investments Group, an estimated $5.64M added.
  • The largest BioSpecifics Technologies Corp. seller in Q4 2019 was Acadian Asset Management, an estimated $6.1M sold.

Based on aggregated 13F filings for Q4 2019.